TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > Australian Prescription Medicine Pathways – Project Orbis

Australian Prescription Medicine Pathways – Project Orbis

Authors: Rob Stringer & Luis Jimenez

Project Orbis is an initiative of the US FDA Oncology Centre of Excellence (OCE). The intent of Project Orbis is to provide a framework for concurrent submission and review of oncology products among international regulators. 1

Whilst the US FDA has facilitated the exchange of selected information and collaboration between international regulators for over 15 years, Project Orbis represents the next level of international regulatory co-operation and transparency, with close proximity filings in several different jurisdictions and a concurrent, yet independent evaluation, by participating agencies accelerated through access to inter-agency regulatory evaluation information. Project Orbis has consistently resulted in remarkably quick regulatory evaluation timelines, and for some territories, substantially earlier regulatory approvals of medicines than would otherwise have been possible.

How do I get involved?

US Companies can be invited by the US FDA OCE to participate in Project Orbis and/or propose applications and the OCE acts as the primary coordinator for the process. Acceptance into the initiative is contingent upon meeting key clinical criteria (for example clinically significant and/or compelling data demonstrating improved safety or efficacy) and a commitment by the applicant to be able to facilitate the submission of applications in close proximity in all participating territories. For US-based entities with limited international operations, this may require either establishment of a legal entity in the intended territory and/or engagement of a 3rd party to act as the applicant.

Once a viable applicant/pathway for regulatory filing has been identified for each of the intended jurisdictions, the FDA will liaise directly with the respective regulatory agencies to inform them of the potential for evaluation under the Project Orbis framework. Once participation by the agency has been confirmed, the application can proceed to the next stage.

Which countries have participated?

To-date, applications facilitated by the US FDA under Project Orbis have involved the following regulatory agencies.

Country Regulatory Authority
Australia Therapeutic Goods Administration (TGA)
Canada Health Canada
Singapore Health Sciences Authority (HSA)
Switzerland Swissmedic

Whilst initial Project Orbis evaluations appeared to predominantly involve Health Canada and/or TGA, more recent reviews have also included Swissmedic and Singapore’s HSA.

What products have been approved in Australia under Project Orbis?

The first action under the international collaboration of Project Orbis was the September 2019 accelerated approval of lenvatinib in combination with pembrolizumab for patients with endometrial carcinoma. 2 The US FDA, the Australian TGA and Health Canada collaboratively reviewed line extension applications for the two oncology drugs, allowing for positive decisions in all three countries. Subsequent Project Orbis approvals have occurred for both line extensions and new entities, including: acalabrutinib (November 2019),3 nivolumab + ipilimumab (July 2020),4 5 ripretinib (July 2020),6 ibrutinib (August 2020),7 8 and tucatinib (August 2020). 9

Type of regulatory pathways?

Due to the collaborative nature of the review, the regulatory pathways which may impact timeline and/or the level of evidence required for the review should be aligned, i.e. if an application will be submitted as a Priority Review in the US, equivalent designations/determinations should be sought in Australia.

USA Australia
Breakthrough Designation No equivalent
Accelerated Approval Provisional Approval
Priority Review Priority Review

How does it work?

Regulatory dossiers must be ideally lodged in close proximity in accordance with each participating agency’s respective regulatory requirements. For Australian submissions, an eCTD regulatory dossier will need to be submitted consisting of an Australian specific Module 1 and accompanying Modules 2-5. Any differences between the components of Modules 2 to 5 should be described and contextualised in Module 1.

Thereafter, the application will proceed as per the designated milestone pathway. Throughout the regulatory evaluation process, whilst the participating regulators will collaborate with each other, they each conduct their own review, and engage directly with the local applicant/sponsor. Participating applicants are requested to ensure that all information request responses submitted to the individual participating Orbis agencies are also provided to all participating Orbis agencies, thereby minimising duplication and allowing for the efficient allocation of regulatory evaluation resource. The only exception to this process is labelling/Product Information request responses which are negotiated directly with the respective regulator.

Advantages of participating in Project Orbis?

Whilst in principle a parallel, independent regulatory review by 5 different regulatory agencies sounds very resource intensive, in practice the real-time collaboration between the agencies can actually reduce the regulatory resources required by both the participating agencies and applicants. Utilisation of common dossiers, shared evaluation questions and responses seems to have resulted in some impressively fast regulatory evaluation timelines. The available Australian regulatory review timelines for products evaluated via Project Orbis are summarised in the following table:

Product Application type No. of working days
lenvatinib / pembrolizumab Line Extension
Provisional Approval
54
acalabrutinib* Line Extension 35
nivolumab / ipilimumab Line Extension 68
ripretinib New Chemical Entity
Priority Review
123
tucatinib New Chemical Entity
Priority Review
113

*regulatory approval for the new entity occurred via a COR-B pathway utilising the US FDA as the Comparable Overseas Regulator, subsequent concurrent review of a line extension via Project Orbis

Other considerations

  • Products participating in US FDA’s OCE Real-Time Oncology Review (RTOR) which permits FDA access to key data prior to the official submission of the NDA, can also participate in Project Orbis, with documents from the RTOR evaluation shared between agencies.
  • For oncology applications which may have already been reviewed by the FDA – a modified Orbis process may be possible, whereby access to the FDA evaluation documentation can be facilitated to abbreviate the regulatory review.
  1. https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis
  2. https://www.tga.gov.au/media-release/provisional-application-receives-approval-through-first-international-collaborative-review-initiative-between-tga-fda-and-hc
  3. https://www.tga.gov.au/media-release/acalabrutinib-receives-tga-approval-cll-and-sll-cancers
  4. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc
  5. https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines
  6. https://www.tga.gov.au/apm-summary/qinlock
  7. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia
  8. https://www.tga.gov.au/apm-summary/tukysa
Contact us
Related posts
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
Recent Blogs
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Provided honest feedback and collaborative working solutions to obstacles

    South Korea based medium sized company
    Manager
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for